These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8575451)

  • 1. Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase.
    Fuller M; Van der Ploeg A; Reuser AJ; Anson DS; Hopwood JJ
    Eur J Biochem; 1995 Dec; 234(3):903-9. PubMed ID: 8575451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
    Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
    Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
    Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species-specific differences in the processing of acid α-glucosidase are due to the amino acid identity at position 201.
    Moreland RJ; Higgins S; Zhou A; VanStraten P; Cauthron RD; Brem M; McLarty BJ; Kudo M; Canfield WM
    Gene; 2012 Jan; 491(1):25-30. PubMed ID: 21963446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease.
    Van Hove JL; Yang HW; Wu JY; Brady RO; Chen YT
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):65-70. PubMed ID: 8552676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
    Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation.
    Nicolino MP; Puech JP; Kremer EJ; Reuser AJ; Mbebi C; Verdière-Sahuqué M; Kahn A; Poenaru L
    Hum Mol Genet; 1998 Oct; 7(11):1695-702. PubMed ID: 9736771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle.
    Van der Ploeg AT; Loonen MC; Bolhuis PA; Busch HM; Reuser AJ; Galjaard H
    Pediatr Res; 1988 Jul; 24(1):90-4. PubMed ID: 2970619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor.
    Moreland RJ; Jin X; Zhang XK; Decker RW; Albee KL; Lee KL; Cauthron RD; Brewer K; Edmunds T; Canfield WM
    J Biol Chem; 2005 Feb; 280(8):6780-91. PubMed ID: 15520017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy.
    Martin-Touaux E; Puech JP; Château D; Emiliani C; Kremer EJ; Raben N; Tancini B; Orlacchio A; Kahn A; Poenaru L
    Hum Mol Genet; 2002 Jul; 11(14):1637-45. PubMed ID: 12075008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
    Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
    Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice.
    Maga JA; Zhou J; Kambampati R; Peng S; Wang X; Bohnsack RN; Thomm A; Golata S; Tom P; Dahms NM; Byrne BJ; LeBowitz JH
    J Biol Chem; 2013 Jan; 288(3):1428-38. PubMed ID: 23188827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
    Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
    Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Pompe's disease with recombinant enzymes].
    Van Hove JL
    Verh K Acad Geneeskd Belg; 1998; 60(4):347-57. PubMed ID: 9883081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.
    Fukuda T; Ahearn M; Roberts A; Mattaliano RJ; Zaal K; Ralston E; Plotz PH; Raben N
    Mol Ther; 2006 Dec; 14(6):831-9. PubMed ID: 17008131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
    Lin CY; Ho CH; Hsieh YH; Kikuchi T
    Gene Ther; 2002 May; 9(9):554-63. PubMed ID: 11973631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.